
    
      This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in
      subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be
      randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.

      Treatment will be continued until 30 days after index event, and primary efficacy
      measurements will be carried out during hospitalization and safety events until 60 days after
      index hospitalisation.
    
  